PainChek has secured a landmark agreement with Sabra Health Care REIT to deploy its AI-powered pain assessment across up to 20,000 beds in North America, marking a pivotal step in its US expansion.
- Master Services Agreement with Sabra REIT covers 329 facilities
- Sabra to fund PainChek deployment at $55-$75 USD per bed annually
- Potential model for replication across other North American healthcare REITs
- Agreement follows PainChek's FDA approval and US market entry
- Sabra obligated to introduce PainChek to all current and future operators
Sabra REIT Deal Opens Door to 20,000 Beds
PainChek Ltd (ASX:PCK) has achieved a significant commercial breakthrough with a Master Services Agreement that will see its AI-driven pain assessment technology deployed across as many as 20,000 beds in North America. The deal with Sabra Health Care REIT (Nasdaq: SBRA), a $5 billion healthcare real estate giant, covers 329 skilled nursing, long-term care, and senior housing facilities across the US and Canada.
Crucially, Sabra will fund PainChek’s solution on behalf of its operators, removing a major financial hurdle for adoption. Pricing is set between $55 and $75 USD per bed per annum, with discounts tied to longer contracts or collaborative research projects. This owner-level endorsement is designed to accelerate uptake and simplify PainChek’s sales process by leveraging Sabra’s influence over its portfolio.
Strategic Milestone After FDA Approval
This agreement follows PainChek’s FDA clearance in 2025, which unlocked the US market and Remote Therapeutic Monitoring reimbursement eligibility, as detailed in prior filings. The Sabra deal represents a tangible commercialisation of that regulatory milestone, transitioning PainChek from market entry to broad-scale deployment. The company is already finalising agreements with an initial five operators within Sabra’s network, with another ten lined up.
Sabra’s commitment to introduce PainChek to all current and future operators in its portfolio significantly boosts the likelihood of widespread adoption without PainChek needing to proportionally scale its sales and marketing efforts. This owner-led funding and distribution model has the potential to be replicated with other healthcare REITs and institutional asset owners, providing a scalable blueprint for PainChek’s North American ambitions.
Broader Implications for Aged Care Technology
With over 36,000 beds across its facilities, Sabra is among the largest specialised healthcare REITs in North America. The scale and capital-light nature of this rollout could reshape how AI-powered pain assessment tools are adopted in aged care settings, potentially setting a precedent for similar partnerships in the sector.
This development builds on PainChek’s recent progress, including strong UK growth with 4,000 new licenses and a 9% revenue increase in aged care, signalling rising global demand for its technology. The Sabra deal is a critical step in translating regulatory approvals and market interest into substantial revenue streams and operational scale.
Philip Daffas, PainChek’s CEO, described the agreement as a blueprint for replicating this model across other US-based REITs, highlighting its potential to drive efficient scale in a fragmented market. The rollout will proceed in stages, with early operator agreements expected to provide valuable momentum.
Bottom Line?
PainChek’s Sabra deal marks a pivotal shift from regulatory approval to large-scale commercial rollout, but execution across operators and replication with other REITs will be key to unlocking sustained growth.
Questions in the middle?
- How quickly will Sabra’s operators adopt PainChek across the 20,000 beds?
- Will other major healthcare REITs follow Sabra’s funding and distribution model?
- How will PainChek balance scaling US operations while maintaining clinical validation standards?